News

Published on 5 Jan 2022 on Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease...

Article preview image

Here's a roundup of top developments in the biotech space over the last 24 hours.

Annexon, Inc. (NASDAQ: ANNX) announced interim data from its Phase 2 clinical trial of ANX005 in patients with Huntington's disease who completed the 24-week treatment period, showing that treatment with ANX005 has been generally well-tolerated, with full target engagement of C1q in both serum and cerebrospinal fluid observed in evaluable patients through the dosing period.

Read the rest of the article
NYSE.PFE price evolution
NYSE.INSP price evolution
NASDAQ.IPHA price evolution
NASDAQ.MRSN price evolution
NASDAQ.ONCT price evolution
NASDAQ.NRXP price evolution
NASDAQ.ANNX price evolution
NYSE.AMRX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
13 Best Ethical Companies to Invest in 2024

In this piece, we will take a look at the 13 best ethical companies to invest in 2024. If you wan...

Insider Monkey via Yahoo Finance 24 Apr 2024
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown -...

Moderna Inc. MRNA is set to clash with Pfizer Inc. PFE and BioNTech SE BNTX in a pivotal London p...

Benzinga 23 Apr 2024
10 Best Performing Biotech ETFs in 2024

In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our ...

Insider Monkey via Yahoo Finance 22 Apr 2024
EU regulators approve Pfizer antibiotic Emblaveo (NYSE:PFE)

EU regulators have approved Pfizer (PFE) and AbbVie’s (ABBV) antibiotic product Emblaveo for the...

Seeking Alpha 22 Apr 2024
11 Best Low Price Pharma Stocks To Invest In

In this piece, we will take a look at the 13 best low price pharma stocks to invest in. If you wa...

Insider Monkey via Yahoo Finance 21 Apr 2024
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a go...

Zacks via Yahoo Finance 19 Apr 2024
Big pharma: cautious optimism ahead of earnings season - analysts

Looking ahead to the pharmaceutical earnings season, UBS expressed cautious optimism when looking...

Proactive Investors 18 Apr 2024
Pfizer-Connect Biopharma deal for inflammatory drug ends

Connect Biopharma (CNTB) terminates licensing deal with Pfizer (PFE) for CBP-174, an oral...

Seeking Alpha 17 Apr 2024
Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff

Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff...

Benzinga via Yahoo Finance 16 Apr 2024
A Win for the SEC on Shadow Trading. Now What?

The lawsuit, which survived both a motion to dismiss (read here) and motion for summary judgment ...

The National Law Review 15 Apr 2024

Copyright Statfolio @ 2024

Social Accounts